Achilleos K, Petrou C, Nicolaidou V, Sarigiannis Y (2025) Beyond efficacy: ensuring safety in peptide therapeutics through immunogenicity assessment. J Pept Sci 31(6):e70016. https://doi.org/10.1002/psc.70016

Article  CAS  PubMed  PubMed Central  Google Scholar 

Afzaal M, Saeed F, Shah YA, Hussain M, Rabail R, Socol CT, Hassoun A, Pateiro M, Lorenzo JM, Rusu AV, Aadil RM (2022) Human gut microbiota in health and disease: unveiling the relationship. Front Microbiol 13(September):1–14. https://doi.org/10.3389/fmicb.2022.999001

Article  Google Scholar 

Al Musaimi O, Lombardi L, Williams DR, Albericio F (2022) Strategies for improving peptide stability and delivery. Pharmaceuticals. https://doi.org/10.3390/ph15101283

Article  PubMed  PubMed Central  Google Scholar 

Alameel T, Almutairdi A, Al-Bawardy B (2023) Emerging therapies for ulcerative colitis: updates from recent clinical trials. Clin Exp Gastroenterol 16(August):147–167. https://doi.org/10.2147/CEG.S375969

Article  CAS  PubMed  PubMed Central  Google Scholar 

Al-jaber H, Biswas KH, Al-mansoori L (2025) Advancing targeted therapy for colorectal cancer: harnessing ligand-directed enzyme prodrug therapy for highly speci fi c interventions. Front Oncol. https://doi.org/10.3389/fonc.2025.1570712

Article  PubMed  PubMed Central  Google Scholar 

Angkeow J, Rothman A, Chaaban L, Paul N, Melia J (2024) Systematic review: outcome prediction in acute severe ulcerative colitis. Gastro Hep Advances 3(2):260–270. https://doi.org/10.1016/j.gastha.2023.11.001

Article  PubMed  Google Scholar 

Antunes JC, Seabra CL, Domingues JM, Teixeira MO, Nunes C, Costa-Lima SA, Homem NC, Reis S, Amorim MTP, Felgueiras HP (2021) Drug targeting of inflammatory bowel diseases by biomolecules. Nanomaterials 11(8):1–25. https://doi.org/10.3390/nano11082035

Article  CAS  Google Scholar 

Baral KC, Choi KY (2025) Barriers and strategies for oral peptide and protein therapeutics delivery: update on clinical advances. Pharmaceutics. https://doi.org/10.3390/pharmaceutics17040397

Article  PubMed  PubMed Central  Google Scholar 

Ben Ghezala I, Charkaoui M, Michiels C, Bardou M, Luu M (2021) Small molecule drugs in inflammatory bowel diseases. Pharmaceuticals 14(7):1–20. https://doi.org/10.3390/ph14070637

Article  CAS  Google Scholar 

Bénard MV, de Goffau MC, Blonk J, Hugenholtz F, van Buuren J, Paramsothy S, Kaakoush NO, Dhaens GRAM, Borody TJ, Kamm MA, Ponsioen CY (2024) Gut microbiota features in relation to fecal microbiota transplantation outcome in ulcerative colitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. https://doi.org/10.1016/j.cgh.2024.10.001

Article  PubMed  Google Scholar 

Bhol NK, Bhanjadeo MM, Singh AK, Dash UC, Ojha RR, Majhi S, Duttaroy AK, Jena AB (2024) The interplay between cytokines, inflammation, and antioxidants: mechanistic insights and therapeutic potentials of various antioxidants and anti-cytokine compounds. Biomed Pharmacother 178:117177. https://doi.org/10.1016/j.biopha.2024.117177

Article  CAS  PubMed  Google Scholar 

Bhutta NK, Xu X, Jian C, Wang Y, Liu Y, Sun J, Han B, Wu S, Javeed A (2024) Gut microbiota mediated T cells regulation and autoimmune diseases. Front Microbiol 15:1477187. https://doi.org/10.3389/fmicb.2024.1477187

Article  PubMed  PubMed Central  Google Scholar 

Blagojevic L, Kamaly N (2025) Nanogels: a chemically versatile drug delivery platform. Nano Today 61:102645. https://doi.org/10.1016/j.nantod.2025.102645

Article  CAS  Google Scholar 

Bretto E, Ribaldone DG, Caviglia GP, Saracco GM, Bugianesi E, Frara S (2023) Inflammatory bowel disease: emerging therapies and future treatment strategies. Biomedicines 11(8):1–33. https://doi.org/10.3390/biomedicines11082249

Article  CAS  Google Scholar 

Buie MJ, Quan J, Windsor JW, Coward S, Hansen TM, King JA, Kotze PG, Gearry RB, Ng SC, Mak JWY, Abreu MT, Rubin DT, Bernstein CN, Banerjee R, Yamamoto-Furusho JK, Panaccione R, Seow CH, Ma C, Underwood FE, Ahuja V, Panaccione N, Shaheen A-A, Holroyd-Leduc J, Kaplan GG, Balderramo D, Chong VH, Juliao-Baños F, Dutta U, Simadibrata M, Kaibullayeva J, Sun Y, Hilmi I, Raja Ali RA, Paudel MS, Altuwaijri M, Hartono JL, Wei SC, Limsrivilai J, El Ouali S, Vergara BI, Dao VH, Kelly P, Hodges P, Miao Y, Li M (2023) Global hospitalization trends for Crohn’s disease and ulcerative colitis in the 21st century: a systematic review with temporal analyses. Clin Gastroenterol Hepatol 21(9):2211–2221. https://doi.org/10.1016/j.cgh.2022.06.030

Article  PubMed  Google Scholar 

Caban M, Lewandowska U (2022) Polyphenols and the potential mechanisms of their therapeutic benefits against inflammatory bowel diseases. J Funct Foods 95:105181. https://doi.org/10.1016/j.jff.2022.105181

Article  CAS  Google Scholar 

Chen G, Xie Y, Peltier R, Lei H, Wang P, Chen J, Hu Y, Wang F, Yao X, Sun H (2016) Peptide-decorated gold nanoparticles as functional nano-capping agent of mesoporous silica container for targeting drug delivery. ACS Appl Mater Interfaces 8(18):11204–11209. https://doi.org/10.1021/acsami.6b02594

Article  CAS  PubMed  Google Scholar 

Chen M, Lan H, Jin K, Chen Y (2023a) Responsive nanosystems for targeted therapy of ulcerative colitis: current practices and future perspectives. Drug Deliv 30(1):2219427. https://doi.org/10.1080/10717544.2023.2219427

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen M, Lan H, Jin K, Chen Y (2023b) Responsive nanosystems for targeted therapy of ulcerative colitis: current practices and future perspectives. Drug Deliv. https://doi.org/10.1080/10717544.2023.2219427

Article  PubMed  PubMed Central  Google Scholar 

Chen S, Saeed AFUH, Liu Q, Jiang Q, Xu H, Xiao GG, Rao L, Duo Y (2023c) Macrophages in immunoregulation and therapeutics. Signal Transduct Target Ther. https://doi.org/10.1038/s41392-023-01452-1

Article  PubMed  PubMed Central  Google Scholar 

Chen S, Qin Z, Zhou S, Xu Y, Zhu Y (2025) The emerging role of intestinal stem cells in ulcerative colitis. Front Med 12(March):1–19. https://doi.org/10.3389/fmed.2025.1569328

Article  Google Scholar 

Cherry LN, Yunker NS, Lambert ER, Vaughan D, Lowe DK (2015) Vedolizumab: an α4β7 integrin antagonist for ulcerative colitis and Crohn’s disease. Ther Adv Chronic Dis 6(5):224–233. https://doi.org/10.1177/2040622315586970

Article  CAS  PubMed  PubMed Central  Google Scholar 

Choe U (2025) Role of dietary fiber and short-chain fatty acids in preventing neurodegenerative diseases through the gut-brain axis. J Funct Foods 129:106870. https://doi.org/10.1016/j.jff.2025.106870

Article  CAS  Google Scholar 

Ciulla MG, Civera M, Sattin S, Kumar K (2023) Nature-inspired and medicinally relevant short peptides. Expl Drug Sci 1(3):140–171. https://doi.org/10.37349/eds.2023.00011

Article  Google Scholar 

Colwill M, Baillie S, Clough J, Pollok R, Poullis A, Patel K, Honap S (2025) Role of mirikizumab in the treatment of inflammatory bowel disease-from bench to bedside. J Clin Med. https://doi.org/10.3390/jcm14031001

Article  PubMed  PubMed Central  Google Scholar 

D’Haens G, Sandborn W, Colombel J, Rutgeerts P, Brown K, Barkay H, Sakov A, Haviv A, Feagan B (2014) A phase II study of laquinimod in Crohn’s disease. Gut. https://doi.org/10.1136/gutjnl-2014-307118

Article  PubMed  Google Scholar 

Dagliyan O, Proctor EA, D’Auria KM, Ding F, Dokholyan NV (2011) Structural and dynamic determinants of protein-peptide recognition. Structure (London, England:1993) 19(12):1837–1845. https://doi.org/10.1016/j.str.2011.09.014

Article  CAS  PubMed  Google Scholar 

Dan N, Samanta K, Almoazen H (2020) An update on pharmaceutical strategies for oral delivery of therapeutic peptides and proteins in adults and pediatrics. Children (Basel). https://doi.org/10.3390/children7120307

Article  PubMed  Google Scholar 

Danese S, Rudziński J, Brandt W, Dupas J-L, Peyrin-Biroulet L, Bouhnik Y, Kleczkowski D, Uebel P, Lukas M, Knutsson M, Erlandsson F, Hansen MB, Keshav S (2015) Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study. Gut 64(2):243–249. https://doi.org/10.1136/gutjnl-2014-308004

Article  CAS  PubMed